Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system

Urology

Volumn 76, Issue 3, 2010, Pages 652-656

  Feifer, Andrew ^a   Xie, Xuanqian ^b   Brophy, James M ^a   Segal, Robert ^a   Kassouf, Wassim ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MITOMYCIN C; ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN;

ARTICLE; BLADDER TUMOR; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; COST BENEFIT ANALYSIS; CYSTECTOMY; CYSTOSCOPY; FOLLOW UP; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MEDICAL FEE; MEDICARE; PRIORITY JOURNAL; TRANSURETHRAL BLADDER TUMOR RESECTION; TRANSURETHRAL RESECTION; URINE CYTOLOGY; COST; ECONOMICS; INTRAVESICAL DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; URINARY BLADDER NEOPLASMS;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; COSTS AND COST ANALYSIS; HUMANS; MITOMYCIN; URINARY BLADDER NEOPLASMS;

EID: 77957706659     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.12.070     Document Type: Article

References (28)

1. D.A. Tolley, M.K. Parmar, K.M. Grigor, G. Lallemand, L.L. Benyon, and J. Fellows The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up J Urol. 155 1996 1223 1228
2. S.A. Brassell, and A.M. Kamat Contemporary intravesical treatment options for urothelial carcinoma of the bladder J Natl Compr Cancer Netw. 4 2006 1027 1036
3. J.A. Smith Jr., R.F. Labasky, J.E. Montie, R.G. Rowland, A.T.K. Cockett, and J.A. Facchia Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS); The American Urological Association J Urol. 163 2000 18901701
4. M.C. Hall, S.S. Chang, G. Dalbagni, S.J. Pruthi, J.D. Seigne, and E.C. Skinner Guidelines for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol. 178 2007 2314 2330
5. R.J. Sylvester, W. Oosterlinck, and A.P. van der Meijden A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials J Urol. 171 2004 2186 2190
6. R. Persad, D. Lammb, M. Brausi, M. Soloway, J. Palou, and M. Colombel Current approaches to the management of non-muscle invasive bladder cancer: comparison of current guidelines and recommendations Eur Urol Supplements 7 10 2008 637 650 1569-9056
7. O. Oge, E. Erdem, N. Atsu, A. Sahin, and H. Ozen Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor Eur Urol. 37 2000 271 274
8. P. Mariappan, and G. Smith A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database J Urol. 173 4 2005 1108 1111 April
9. C.S. Loh, A.V. Spedding, M.T. Ashworth, W.E. Kenyon, and A.D. Desmond The value of exfoliative urine cytology in combination with flexible cystoscopy in the diagnosis of recurrent transitional cell carcinoma of the urinary bladder Br J Urol. 77 1996 655 658
10. D. Schrag, L.J. Hsieh, F. Rabbani, P.B. Bach, H. Herr, and C.B. Begg Adherence to surveillance among patients with superficial bladder cancer J Natl Cancer Inst. 95 2003 588 597 (Pubitemid 36553505)
11. M.S. Soloway Intravesical and systemic chemotherapy in the management of superficial bladder cancer Urol Clin North Am. 11 1984 623 635
12. W. Oosterlinck, K.H. Kurth, F.H. Schrder, J. Bultinck, B. Hammond, and R. Sylvester A prospective European Organization for Research and Treatment of Cancer genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder J Urol. 149 1993 749 752
13. E. Solsona, I. Iborra, J.V. Rics, J.L. Monrs, J. Casanova, and R. Dumont Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow up J Urol. 161 1999 1120 1123
14. W. Kassouf, A.M. Kamat, A. Zlotta, B.H. Bochner, R. Moore, and A. So Canadian guidelines for treatment of non-muscle invasive bladder cancera focus on intravesical therapy http://www.cua.org/guidelines
15. American Urological Association The management of bladder cancer: diagnosis and treatment recommendations http://www.auanet.org/content/ guidelines-and-quality-care/clinical-guidelines
16. M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Bhle, and J. Palou-Redorta EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol. 54 2008 303 314
17. G.F. Riley, A.L. Potosky, J.D. Lubitz, and L.G. Kessler Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis Med Care 33 1995 828 841
18. N.S. Clarke, S. Basu, S. Prescott, and R. Puri Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists BJU Int. 97 2006 716 719
19. R. Madeb, D. Golijanin, K. Noyes, S. Fisher, J.J. Stephenson, S.R. Long, J. Knopf, G.H. Lyman, and E.M. Messing Treatment of nonmuscle invading bladder cancer: do physicians in the US practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors Cancer 115 12 2009 2660 2670
20. E. Solsona, I. Iborra, J.V. Rics, J.L. Monrs, J. Casanova, and R. Dumont Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup J Urol. 161 1999 1120 1123
21. J.E. Montie, P.E. Clark, M.A. Eisenberger, R. El-Galley, R.E. Greenberg, and H.W. Herr National Comprehensive Cancer Network Bladder cancer J Natl Compr Cancer Netw. 7 2009 8 39
22. M.S. Cookson, H.W. Herr, Z.F. Zhang, S. Soloway, P.C. Sogani, and W.R. Fair The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol. 158 1997 62 67
23. W.B. Van den Hout, Y.P. Goekoop-Ruiterman, C.F. Allaart, J.K. De Vries-Bouwstra, J.M. Hazes, and P.J. Kerstens Cost-utility of treatment strategies in patients with recent-onset rheumatoid arthritis Arthritis Rheum. 61 2009 291 299
24. J.M. Pow-Sang, and J.D. Seigne Contemporary management of superficial bladder cancer Cancer Control 7 2000 335 339
25. P.H. Smith The costs of intravesical chemotherapy Biol Review 185B 1985 39 44
26. E.C. Baselli, and R.E. Greenberg Intravesical therapy for superficial bladder cancer Oncology (Huntingt) 14 2000 719 729
27. M.F. Botteman, C.L. Pashos, A. Radaelli, B. Laskin, and R. Hauser The health economics of bladder cancer A comprehensive review of the published literature Pharmacoeconomics 21 2003 1315 1330
28. P.K. Rao, and J.S. Jones Routine perioperative chemotherapy instillation with initial bladder tumor resection A reconsideration of economic benefits Cancer 115 2009 997 1004